Mirxes’ Post

🚀 Ready for SLAS (Society for Laboratory Automation and Screening) Conference 2024 in Barcelona! We are excited to go on our first conference with our brand new DIANA Cyclin Dependent Kinases (CDKs) panel based on our unique DIANA Technology. The CDK family represents a highly promising avenue for the advancement of cancer therapy, and we are looking forward to meet you there and talk about news in CDKs assays development! 🔬 Key Highlights: Selective Profiling: We’ve successfully profiled target compounds against 24 Cyclin Dependent Kinases (CDKs), providing crucial data to further our understanding in this area. Innovative Development: Exciting progress on further development of our DIANA General Kinase Panel kinase that will cover the entire human kinome, enhancing our capability to tackle complex diseases.   🌟 Main Features of DIANA: Proprietary Technology: Leveraging our patented DIANA technology. High Throughput: Utilizes a 384-well plate format to accelerate outcomes. Cost Efficiency: Reduced reagent consumption makes this method not only innovative but also cost-effective. Precision: Quantitative PCR-based readout allows for determination of inhibition constants (Ki) from a single well. 🕓 And when? 29th May, Poster Session B, 1145-B, Track: Screening Applications & Diagnostics All of your questions will be answered by our scientists Ilona Kalasova and Lucia Bialesova! 🙌 For more info: https://lnkd.in/eKUhRAKp #DrugDiscovery #Innovation #DIANATechnology #PharmaIndustry #SLASEurope2024

MicroRNA (miRNA) has surged into the spotlight this week, thanks to Victor Ambros and Gary Ruvkun's Nobel Prize win for its discovery. Once a virtual unknown (pre-COVID), miRNA has rapidly evolved into a mainstream concept, culminating in this prestigious award. As the only private company in Singapore dedicated to miRNA research and development, #Mirxes has garnered increased attention following the Nobel Prize announcement. Many are curious about our role in the broader miRNA ecosystem and how we contribute to advancing this rapidly evolving field. We would like to take this opportunity to share about Mirxes’ journey and mission. Mirxes Co-Founder, Chairman and Chief Scientific Advisor, Assoc Prof Too Heng-Phon, has been a leading figure in miRNA research for two decades, pioneering innovative methods and assays for the accurate detection of miRNA biomarkers. His miRNA qPCR assay platform technology, patented and published in 2010, laid the foundation for the establishment of Mirxes. His groundbreaking work was also recognised with prestigious awards, including the President's Technology Award 2021. Assoc Prof Too's former PhD students, Dr Lihan Zhou and Dr Zou Ruiyang, joined him on his mission, and they co-founded Mirxes in 2014. Together, they commercialised our miRNA qPCR assay platform technology, applying it to the discovery of biomarkers for early detection of cancer and other diseases. The technology is now a valuable tool for life science researchers worldwide, contributing to basic research and clinical biomarker discovery across numerous disease types. The technology also led to the development of Mirxes' flagship product, GASTROClear, an innovative blood test for the early detection of gastric cancer. GASTROClear has since received the CE mark in 2017, regulatory approval from Singapore’s Health Sciences Authority in 2019, and US FDA breakthrough device status in 2023. While the discovery of miRNA being recognised with a Nobel Prize is a significant milestone, the journey to accurately detect different miRNA variants and understand their specific influences is ongoing. Mirxes is committed to advancing miRNA research and harnessing its potential for precision medicine, with the goal of turning cancer into a treatable disease. #preventivehealthcare #precisionmedicine #biotech #researchanddevelopment #earlydetectionsaveslives #healthcare #cancerearlydetection #miRNA #research *Photo: Taken some years ago, when Assoc Prof Too, Dr Zhou and Dr Zou just started Mirxes.

🚀 Exciting Research Update! 🚀 We are thrilled to share that Dmytro Pastukh from Diagnostics @Fraunhofer IMM is embarking on a 3-month research stay at INTERFIBIO under the supervision of Dr. Ciara O' Sullivan and Dr. Vasoula Skouridou. Dmytro’s research focuses on the dynamic and increasingly crucial field of on-chip recombinase polymerase amplification for point-of-care settings. As at INTERFIBIO, the current research goal of the cancer and infection diagnostics group at Fraunhofer IMM is to address the emerging and future paradigm of personalised medicine in which the detection of multiple biomarkers plays a pivotal role #cfDNA. During his time at INTERFIBIO, Dmytro will concentrate on developing solid-phase amplification systems to facilitate multiplexed detection, pushing the boundaries of diagnostic capabilities. INTERFIBIO has a long-standing collaboration with Fraunhofer-IMM, having worked together on over 10 EU-financed projects since 2003 and publishing in high-impact factor peer-reviewed journals. Currently, Interfibio and Fraunhofer-IMM are collaborating on three EU-financed projects. Interfibio is developing solid-phase amplification strategies for detecting SNPs, genes, and aptamer-based protein detection, while Fraunhofer-IMM is creating the prototype microsystem to house all reagents and detection devices. This partnership highlights the excellent complementarity between our teams. Stay tuned for more updates as we continue to innovate and drive forward the future of diagnostics! #Research #Innovation #Diagnostics #PersonalizedMedicine #Collaboration #Biomarkers

🌟 Exciting News! 🌟 I am thrilled to announce the publication of our research article, "Small RNAs in Plasma Extracellular Vesicles Define Biomarkers of Premanifest Changes in Huntington’s Disease," in the Journal of Extracellular Vesicles. 🚀 After five years of hard work and collaboration, our work is out! Here, we have identified small RNAs (sRNAs) in plasma extracellular vesicles (EVs) as potential biomarkers for early detection of Huntington’s Disease (HD). Our study shows that specific EV-sRNAs are downregulated in HD mutation carriers, correlating with cognitive performance in the premanifest stages of the disease. The identification of reliable preclinical biomarkers is an unmet need, critical for improving the design and efficacy of clinical trials aimed at mitigating the disease progression. 👏 A huge thank you to my incredible co-authors and everyone who supported this journey! Marina Herrero Lorenzo Eulalia Marti Saul Martinez Horta Jaime Kulisevsky Georgia Escaramis Rocío Pérez González, PhD 🔗 Read the full article: https://lnkd.in/dj5nqmtw #HuntingtonsDisease #Biomarkers #Research #ExtracellularVesicles #Science #TeamWork #smallRNAs #microRNAs #miRNAs #Exosomes #clinicaltrials

As announced recently TNO will present the results of resmetirom in its translational mouse model of MASH at #EASLCongress in Milan! Meet Eveline Gart at her poster “Resmetirom protects against diet-induced MASLD and reduces atherogenic risk factors in obese Ldlr-/-.Leiden mice” (no.2987) on Thursday the 6th of June. And we will present more for instance on Cenicriviroc; Martine Morrison will present her poster “Treatment with the CCR2/CCR5 antagonist Cenicriviroc does not affect MASH and fibrosis development in Ldlr-/-.Leiden mice, translational to clinical phase 3 trial results” (no.2595) also on the 6th. Last but not least we will show our work on biomarkers in MASLD. One on a biomarker panel for hepatic fibrosis: “Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD” (no.2887) presented by Eveline and one the novo lipogenesis: “ Metabolic flux analysis using a 14C microtracer approach combined with accelerator mass spectrometry analysis - a proof of concept study on de novo lipogenesis” by Martine If you wish to learn more both Eveline, Martine or José Inia, who will also attend this event, please reach out to them or me to schedule a meeting. If you wish to receive a copy of a poster after the event, please reach out to me. #translationalresearch #preclinicalresearch #MASH #NASH #MASLD #NAFLD #fibrosis #biomarkers #resmetirom #TNOHealthyLiving

Announcement: Overarching agreement with Dundee University and Initiation of Evaluation project.    We are thrilled to announce the signature of an over-arching agreement with the University of Dundee and their Drug Discovery Unit, University of Dundee (DDU) to access research relating to novel therapeutic candidates.    The first Evaluation Agreement under the framework focuses on investigating a lead series of therapeutic candidates in the increasingly important research area of pro-senescence (selectively promoting ageing of cancer cells to cease growth in tumours). This exciting area of research has the potential to be effective in treating multiple cancer types, and also many other disease areas, including those associated with healthy ageing.    This work builds upon previous ground-breaking research by Dundee and Barts Charity funded research by Prof Cleo Bishop, Professor of Senescence and Director of the Queen Mary University of London Phenotypic Screening Facility.    Speaking about the agreement, ValiRx CEO Dr Suzy Dilly said: "We are delighted to be able to streamline the process of reviewing and accessing the excellent research from the University of Dundee's DDU, which will help to bring on evaluation projects more quickly."    Professor David Gray, Head of Biology and innovative targets portfolio lead at the DDU commented "We are delighted that our UKRI Impact Accelerator Award has enabled us to translate the groundbreaking work of our collaborator Cleo Bishop at Queen Mary University London, to the point where ValiRx see the potential for treating patients."    Watch the announcement video, recorded by BRR Media, where ValiRx CSO Dr Cathy Tralau-Stewart explains the agreement in more detail: https://lnkd.in/gVcwHvPZ   #Assays #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch

#Mirxes is excited and honoured to announce a groundbreaking partnership with Universiti Kebangsaan Malaysia (UKM) to advance colorectal cancer early detection in Malaysia! The #MOU signed today, witnessed by Malaysian Prime Minister Anwar Ibrahim and Science, Technology and Innovation Minister Chang Lih Kang, marks a significant milestone for Mirxes as we expand our presence in Malaysia. By combining UKM’s world-class cancer and molecular biology research with our proprietary #miRNA technology, and leveraging archived biospecimens from Medical Molecular Biology Institute (UMBI) and The Malaysian Cohort Biobank, Southeast Asia's largest biobank, we will identify crucial #biomarkers that are needed for an accurate and sensitive blood-based colorectal cancer early detection test. And it does not stop here. This partnership also paves the way for the potential development and commercialisation of a wider range of made-in-Malaysia blood-based cancer early detection tests such as those for stomach and lung cancers. “A strong and like-minded local partner like UKM is crucial for the deployment of our proprietary miRNA technology and commercialisation of novel cancer screening tests,” said Dr Lihan Zhou, Co-Founder and CEO of Mirxes. “Together, we’re committed to co-developing and making accessible our portfolio of blood-based cancer early detection tests in Malaysia.” #preventivehealthcare #precisionmedicine #biotech #researchanddevelopment #earlydetection #earlydetectionsaveslives #healthcare #cancerearlydetection #RNA #research #earlydetection #partnership #collaboration #molecularbiology #colorectalcancer

We are pleased to announce that ALZpath Inc. has entered a strategic partnership with Bio-Techne® to advance neurodegenerative disease research! ALZpath's pTau217 antibody will now be incorporated into Bio-Techne's Simple Plex™ assays on the Ella™ platform. This collaboration brings the launch of the Simple Plex Human Phospho-Tau (T217) ALZpath Assay—a tool designed for Alzheimer's disease researchers to achieve accurate, sensitive, and high-precision results. The Ella platform offers researchers decentralized, hands-free immunoassays with results in just 90 minutes, streamlining workflows and enabling rapid insights into biomarkers like pTau217. "As cases of Alzheimer’s disease continue to rise worldwide, this collaboration provides an opportunity to leverage our proprietary pTau217 antibody to advance promising research and development of new treatments,” said Chad Holland, CEO and President of ALZpath. This partnership marks a vital step toward expanding access to advanced diagnostic tools and accelerating the development of new treatments. 📌 Learn more about this exciting partnership in our press release: https://lnkd.in/g9SaGQ3U 📌Visit our website for more details: https://alzpath.bio #ALZpath #BioTechne #NeurodegenerativeDisease #AlzheimersResearch #pTau217

Extracellular Vesicle analysis using APD based Flow Cytometer #EV #Nano #CytoFlex #ExtracellularVesicles

🌟 Volume 38 Issue 8, our March issue is available online 🌟 Thrilled to introduce one of the research articles in our latest issue published in Biomaterials Application! 📚 Lu et al. investigated the role of HOTAIR and the Hedgehog-Gli1 pathway in EGFR-TKIs resistance in non-small cell carcinoma, paving the way for innovative cancer treatment strategies. 💡 🌐 Key Findings: ✅ Sodium alginate microspheres encapsulating HOTAIR siRNA (SA/HOTAIR siRNA) effectively combat EGFR-TKIs resistance ✅ Demonstrated excellent biocompatibility with high encapsulation efficiency and drug-loading capacity ✅ HOTAIR siRNA inhibits proliferation, migration, and invasion while promoting apoptosis in gefitinib-resistant cells ✅ Downregulation of Hedgehog-Gli1 pathway and anti-apoptotic proteins confirmed in animal experiments ✅ Clinical research highlights the potential of monitoring HOTAIR expression to predict EGFR-TKIs efficacy in NSCLC patients 🔬 Scientific Advancements: 🔍 Innovative drug delivery system for combating acquired resistance to EGFR-TKIs 🌱 Insights into HOTAIR's role in modulating EGFR-TKIs resistance via Hedgehog-GLi1 pathway 👩🔬 Implications for Cancer Treatment: 🚀 Introduction of a reliable and long-lasting approach to tackle acquired resistance to EGFR-TKIs ~~~~ Read the full article here: https://lnkd.in/eRfid-sD #CancerResearch #EGFR #DrugResistance #Innovation #ResearchHighlight #Sage #JournalofBiomaterialsApplication Journal Page~~~ https://lnkd.in/ebRgVYuC